Bipolar disorder: Recent clinical trials and emerging therapies for depressive episodes and maintenance treatment

Drug Discovery Today

Volumn 19, Issue 11, 2014, Pages 1792-1800

  Garay, Ricardo P ^a,b   Llorca, Pierre Michel ^c   Young, Allan H ^d   Hameg, Ahcène ^b   Samalin, Ludovic ^c  

^a Universite Paris Sud   (France)

^b Craven ^*  (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ARMODAFINIL; ASENAPINE; CARIPRAZINE; FLUOXETINE PLUS OLANZAPINE; INOSITOL DERIVATIVE; LAMOTRIGINE; LISDEXAMFETAMINE; LITHIUM; LURASIDONE; MIFEPRISTONE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RAMELTEON; SCYLLO INOSITOL; UNCLASSIFIED DRUG; VALPROIC ACID; ANTICONVULSIVE AGENT;

BIPOLAR DISORDER; DRUG CLASSIFICATION; HUMAN; MAINTENANCE THERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ANIMAL; DEPRESSION; DRUG DEVELOPMENT;

ANIMALS; ANTICONVULSANTS; BIPOLAR DISORDER; DEPRESSION; DRUG DISCOVERY; HUMANS;

EID: 84910630402     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.07.010     Document Type: Review

References (44)

1. A. Fagiolini Prevalence, chronicity, burden and borders of bipolar disorder J. Affect. Disord. 148 2013 161 169
2. X. Gonda Suicidal behavior in bipolar disorder: epidemiology, characteristics and major risk factors J. Affect. Disord. 143 2012 16 26
3. D.J. Kupfer The increasing medical burden in bipolar disorder J. Am. Med. Ass. 293 2005 2528 2530
4. M.L. Phillips, and D.J. Kupfer Bipolar disorder diagnosis: challenges and future directions Lancet 381 2013 1663 1671
5. N. Craddock, and P. Sklar Genetics of bipolar disorder Lancet 381 2013 1654 1662
6. L.B. Alloy The psychosocial context of bipolar disorder: environmental, cognitive, and developmental risk factors Clin. Psychol. Rev. 25 2005 1043 1075
7. APA American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision) Am. J. Psychiatry 159 Suppl. 4 2002 1 50
8. J.R. Geddes, and D.J. Miklowitz Treatment of bipolar disorder Lancet 381 2013 1672 1682
9. P.A. Keedwell, and A.H. Young Emerging drugs for bipolar depression: an update Expert Opin. Emerg. Drugs 19 2014 25 36
10. R.S. Mc Intyre A review of FDA-approved treatment options in bipolar depression CNS Spectr. 18 Suppl. 1 2013 4 20
11. NICE Bipolar Disorder (2006) Clinical Guidance no. 38. Available at: http://www.nice.org.uk/guidance/CG38
12. L. Samalin Lithium and anticonvulsants in bipolar depression Encephale 37 Suppl. 3 2011 203 208
13. R.J. Baldessarini Bipolar depression: overview and commentary Harvard Rev. Psychiatry 18 2010 143 157
14. M. Leboyer, and P.M. Llorca Bipolar depression Encephale 37 Suppl. 3 2011 161 162
15. V. Selle Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics Pharmacopsychiatry 47 2014 43 52
16. T.A. Ketter Nosology, diagnostic challenges, and unmet needs in managing bipolar disorder J. Clin. Psychiatry 71 2010 e27
17. M.T. Silva Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis J. Affect. Disord. 146 2013 310 318
18. M. Sanford, and G.M. Keating Quetiapine: a review of its use in the management of bipolar depression CNS Drugs 26 2012 435 460
19. S.C. Stoner, and H.A. Pace Asenapine: a clinical review of a second-generation antipsychotic Clin. Ther. 34 2012 1023 1040
20. L. Samalin Clinical potential of lurasidone in the management of schizophrenia Ther. Clin. Risk Manag. 7 2011 239 250
21. J.R. Calabrese Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study J. Clin. Psychiatry 71 2010 1363 1370
22. M. Miyamoto Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders CNS Neurosci. Ther. 15 2009 32 51
23. R.S. Mc Intyre The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder Human Psychopharmacol. Clin. Expl. 28 2013 421 427
24. L. Citrome Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy Adv. Therapy 30 2013 102 113
25. S.J. Kim Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression J. Affect. Disord. 157 2014 33 40
26. Y.S. Woo Lurasidone as a potential therapy for bipolar disorder Neuropsychiatr. Dis. Treat. 9 2013 1521 1529
27. S.L. Mc Elroy A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance Intl. Clin. Psychopharmacol. 26 2011 48 53
28. S. Leucht Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Lancet 382 2013 951 962
29. E.R. Norris A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder J. Affect. Disord. 144 2013 141 147
30. J. Liu, and L.N. Wang Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis Int. J. Clin. Practice 66 2012 867 873
31. A.D. Krystal Ramelteon. Hypnotic agent targets delayed sleep onset Curr. Psychiatry 4 2005 11
32. J.G. Reid Lamotrigine in psychiatric disorders J. Clin. Psychiatry 74 2013 675 684
33. M. Tohen Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies J. Affect. Disord. 149 2013 196 201
34. K. McKeage Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder CNS Drugs 28 2014 171 183
35. C.M. Canuso Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms Schizophrenia Res. 113 2009 56 64
36. K. Ma Scyllo-inositol, preclinical, and clinical data for alzheimer's disease Adv. Pharmacol. 64 2012 177 212
37. Y. Swica Acceptability of home use of mifepristone for medical abortion Contraception 88 2013 122 127
38. S. Watson A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression Biol. Psychiatry 72 2012 943 949
39. J. Berwaerts A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode J. Affect. Disord. 138 2012 247 258
40. L. Citrome Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed J. Affect. Disord. 155 2014 20 27
41. A. Besga Discovering Alzheimer's disease and bipolar disorder white matter effects building computer aided diagnostic systems on brain diffusion tensor imaging features Neurosci. Lett. 520 2012 71 76
42. J. Angst DSM-IV diagnosis in depressed primary care patients with previous psychiatric ICD-10 bipolar disorder J. Affect. Disord. 152-154 2014 295 298
43. G. Parker Differentiation of bipolar I and II disorders by examining for differences in severity of manic/hypomanic symptoms and the presence or absence of psychosis during that phase J. Affect. Disord. 150 2013 941 947
44. J.M. Azorin Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism Neuropsychiatr. Dis. Treat. 6 2010 37 46